[Federal Register: June 22, 2005 (Volume 70, Number 119)]
[Notices]
[Page 36159-36164]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr22jn05-103]
-----------------------------------------------------------------------
ENVIRONMENTAL PROTECTION AGENCY
[OPP-2005-0032; FRL-7718-7]
Propazine; Notice of Filing a Pesticide Petition to Establish a
Tolerance for a Certain Pesticide Chemical in or on Food
AGENCY: Environmental Protection Agency (EPA).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces the initial filing of a pesticide
petition proposing the establishment of regulations for residues of a
certain pesticide chemical in or on various food commodities.
DATES: Comments, identified by docket identification (ID) number OPP-
2005-0032, must be received on or before July 22, 2005.
ADDRESSES: Comments may be submitted electronically, by mail, or
through hand delivery/courier. Follow the detailed instructions as
provided in Unit I. of the SUPPLEMENTARY INFORMATION.
FOR FURTHER INFORMATION CONTACT: Jim Tompkins, Registration Division
(7505C), Office of Pesticide Programs, Environmental Protection Agency,
1200 Pennsylvania Ave., NW., Washington, DC 20460-0001; telephone
number: (703) 305-5697; e-mail address: tompkins.jim@epa.gov.
SUPPLEMENTARY INFORMATION:
I. General Information
A. Does this Action Apply to Me?
You may be potentially affected by this action if you an
agricultural producer, food manufacturer, or
[[Page 36160]]
pesticide manufacturer. Potentially affected entities may include, but
are not limited to:
Crop production (NAICS 111)
Animal production (NAICS 112)
Food manufacturing (NAICS 311)
Pesticide manufacturing (NAICS 32532)
This listing is not intended to be exhaustive, but rather provides
a guide for readers regarding entities likely to be affected by this
action. Other types of entities not listed in this unit could also be
affected. The North American Industrial Classification System (NAICS)
codes have been provided to assist you and others in determining
whether this action might apply to certain entities. If you have any
questions regarding the applicability of this action to a particular
entity, consult the person listed under FOR FURTHER INFORMATION
CONTACT.
B. How Can I Get Copies of this Document and Other Related Information?
1. Docket. EPA has established an official public docket for this
action under docket ID number OPP-2005-0032. The official public docket
consists of the documents specifically referenced in this action, any
public comments received, and other information related to this action.
Although, a part of the official docket, the public docket does not
include Confidential Business Information (CBI) or other information
whose disclosure is restricted by statute. The official public docket
is the collection of materials that is available for public viewing at
the Public Information and Records Integrity Branch (PIRIB), Rm. 119,
Crystal Mall 2, 1801 S. Bell St., Arlington, VA. This docket
facility is open from 8:30 a.m. to 4 p.m., Monday through Friday,
excluding legal holidays. The docket telephone number is (703) 305-
5805.
2. Electronic access. You may access this Federal Register document
electronically through the EPA Internet under the ``Federal Register''
listings at http://www.epa.gov/fedrgstr/.
An electronic version of the public docket is available through
EPA's electronic public docket and comment system, EPA Dockets. You may
use EPA Dockets at http://www.epa.gov/edocket/ to submit or view public
comments, access the index listing of the contents of the official
public docket, and to access those documents in the public docket that
are available electronically. Although, not all docket materials may be
available electronically, you may still access any of the publicly
available docket materials through the docket facility identified in
Unit I.B.1. Once in the system, select ``search,'' then key in the
appropriate docket ID number.
Certain types of information will not be placed in the EPA Dockets.
Information claimed as CBI and other information whose disclosure is
restricted by statute, which is not included in the official public
docket, will not be available for public viewing in EPA's electronic
public docket. EPA's policy is that copyrighted material will not be
placed in EPA's electronic public docket but will be available only in
printed, paper form in the official public docket. To the extent
feasible, publicly available docket materials will be made available in
EPA's electronic public docket. When a document is selected from the
index list in EPA Dockets, the system will identify whether the
document is available for viewing in EPA's electronic public docket.
Although, not all docket materials may be available electronically, you
may still access any of the publicly available docket materials through
the docket facility identified in Unit I.B. EPA intends to work towards
providing electronic access to all of the publicly available docket
materials through EPA's electronic public docket.
For public commenters, it is important to note that EPA's policy is
that public comments, whether submitted electronically or on paper,
will be made available for public viewing in EPA's electronic public
docket as EPA receives them and without change, unless the comment
contains copyrighted material, CBI, or other information whose
disclosure is restricted by statute. When EPA identifies a comment
containing copyrighted material, EPA will provide a reference to that
material in the version of the comment that is placed in EPA's
electronic public docket. The entire printed comment, including the
copyrighted material, will be available in the public docket.
Public comments submitted on computer disks that are mailed or
delivered to the docket will be transferred to EPA's electronic public
docket. Public comments that are mailed or delivered to the docket will
be scanned and placed in EPA's electronic public docket. Where
practical, physical objects will be photographed, and the photograph
will be placed in EPA's electronic public docket along with a brief
description written by the docket staff.
C. How and to Whom Do I Submit Comments?
You may submit comments electronically, by mail, or through hand
delivery/courier. To ensure proper receipt by EPA, identify the
appropriate docket ID number in the subject line on the first page of
your comment. Please ensure that your comments are submitted within the
specified comment period. Comments received after the close of the
comment period will be marked ``late.'' EPA is not required to consider
these late comments. If you wish to submit CBI or information that is
otherwise protected by statute, please follow the instructions in Unit
I.D. Do not use EPA Dockets or e-mail to submit CBI or information
protected by statute.
1. Electronically. If you submit an electronic comment as
prescribed in this unit, EPA recommends that you include your name,
mailing address, and an e-mail address or other contact information in
the body of your comment. Also, include this contact information on the
outside of any disk or CD ROM you submit, and in any cover letter
accompanying the disk or CD ROM. This ensures that you can be
identified as the submitter of the comment and allows EPA to contact
you in case EPA cannot read your comment due to technical difficulties
or needs further information on the substance of your comment. EPA's
policy is that EPA will not edit your comment, and any identifying or
contact information provided in the body of a comment will be included
as part of the comment that is placed in the official public docket,
and made available in EPA's electronic public docket. If EPA cannot
read your comment due to technical difficulties and cannot contact you
for clarification, EPA may not be able to consider your comment.
i. EPA Dockets. Your use of EPA's electronic public docket to
submit comments to EPA electronically is EPA's preferred method for
receiving comments. Go directly to EPA Dockets at http://www.epa.gov/edocket/
, and follow the online instructions for submitting comments.
Once in the system, select ``search,'' and then key in docket ID number
OPP-2005-0032. The system is an ``anonymous access'' system, which
means EPA will not know your identity, e-mail address, or other contact
information unless you provide it in the body of your comment.
ii. E-mail. Comments may be sent by e-mail to opp-docket@epa.gov,
Attention: Docket ID number OPP-2005-0032. In contrast to EPA's
electronic public docket, EPA's e-mail system is not an ``anonymous
access'' system. If you send an e-mail comment directly to the docket
without going through EPA's electronic public docket, EPA's e-mail
system automatically captures your e-mail address. E-mail addresses
that are automatically
[[Page 36161]]
captured by EPA's e-mail system are included as part of the comment
that is placed in the official public docket, and made available in
EPA's electronic public docket.
iii. Disk or CD ROM. You may submit comments on a disk or CD ROM
that you mail to the mailing address identified in Unit I.C.2. These
electronic submissions will be accepted in WordPerfect or ASCII file
format. Avoid the use of special characters and any form of encryption.
2. By mail. Send your comments to: Public Information and Records
Integrity Branch (PIRIB) (7502C), Office of Pesticide Programs (OPP),
Environmental Protection Agency, 1200 Pennsylvania Ave., NW.,
Washington, DC 20460-0001, Attention: Docket ID number OPP-2005-0032.
3. By hand delivery or courier. Deliver your comments to: Public
Information and Records Integrity Branch (PIRIB), Office of Pesticide
Programs (OPP), Environmental Protection Agency, Rm. 119, Crystal Mall
2, 1801 S. Bell St., Arlington, VA, Attention: Docket ID
number OPP-2005-0032. Such deliveries are only accepted during the
docket's normal hours of operation as identified in Unit I.B.1.
D. How Should I Submit CBI to the Agency?
Do not submit information that you consider to be CBI
electronically through EPA's electronic public docket or by e-mail. You
may claim information that you submit to EPA as CBI by marking any part
or all of that information as CBI (if you submit CBI on disk or CD ROM,
mark the outside of the disk or CD ROM as CBI and then identify
electronically within the disk or CD ROM the specific information that
is CBI). Information so marked will not be disclosed except in
accordance with procedures set forth in 40 CFR part 2.
In addition to one complete version of the comment that includes
any information claimed as CBI, a copy of the comment that does not
contain the information claimed as CBI must be submitted for inclusion
in the public docket and EPA's electronic public docket. If you submit
the copy that does not contain CBI on disk or CD ROM, mark the outside
of the disk or CD ROM clearly that it does not contain CBI. Information
not marked as CBI will be included in the public docket and EPA's
electronic public docket without prior notice. If you have any
questions about CBI or the procedures for claiming CBI, please consult
the person listed under FOR FURTHER INFORMATION CONTACT.
E. What Should I Consider as I Prepare My Comments for EPA?
You may find the following suggestions helpful for preparing your
comments:
1. Explain your views as clearly as possible.
2. Describe any assumptions that you used.
3. Provide copies of any technical information and/or data you used
that support your views.
4. If you estimate potential burden or costs, explain how you
arrived at the estimate that you provide.
5. Provide specific examples to illustrate your concerns.
6. Make sure to submit your comments by the deadline in this
notice.
7. To ensure proper receipt by EPA, be sure to identify the docket
ID number assigned to this action in the subject line on the first page
of your response. You may also provide the name, date, and Federal
Register citation.
II. What Action is the Agency Taking?
EPA has received a pesticide petition as follows proposing the
establishment and/or amendment of regulations for residues of a certain
pesticide chemical in or on various food commodities under section 408
of the Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. 346a.
EPA has determined that this petition contains data or information
regarding the elements set forth in FFDCA section 408(d)(2); however,
EPA has not fully evaluated the sufficiency of the submitted data at
this time or whether the data support granting of the petition.
Additional data may be needed before EPA rules on the petition.
List of Subjects
Environmental protection, Agricultural commodities, Feed
additives, Food additives, Pesticides and pests, Reporting and
recordkeeping requirements.
Dated: June 3, 2005.
Lois Rossi,
Director, Registration Division, Office of Pesticide Programs.
Summary of Petition
The petitioner's summary of the pesticide petition is printed below
as required by FFDCA section 408(d)(3). The summary of the petition was
prepared by Griffin Corporation, and represents the view of the
petitioner. The petition summary announces the availability of a
description of the analytical methods available to EPA for the
detection and measurement of the pesticide chemical residues or an
explanation of why no such method is needed.
Griffin Corporation
PP 7F4837
EPA has received a pesticide petition (PP 7F4837) from Griffin
Corporation, P.O. Box 1847, Valdosta, GA 31603-1847 proposing, pursuant
to section 408(d) of the Federal Food, Drug, and Cosmetic Act (FFDCA),
21 U.S.C. 346a(d), to amend 40 CFR part 180, by establishing a
tolerance for residues of propazine 2-chloro-4,6- bis(isopropyamine)-s-
triazine and its 2 chloro metabolites, 2-amino-4-chloro, 6-
isopropylamino-s-triazine (G-30033) and 2,4-diamino-6-chloro-striazine
(G-28273) in or on the raw agricultural commodity sorghum, stover,
forage, and grain at 0.25 parts per million (ppm). EPA has determined
that the petition contains data or information regarding the elements
set forth in section 408(d)(2) of the FFDCA; however, EPA has not fully
evaluated the sufficiency of the submitted data at this time or whether
the data support granting of the petition. Additional data may be
needed before EPA rules on the petition.
A. Residue Chemistry
1. Plant metabolism. In sorghum, metabolism occurs by the three
following reactions: N-dealkylation of the side-chains, hydrolytic
dehalogenation or nucleophilic displacement of the 2-chloro group with
glutathione (GSH). The dehalogenation and formation of GSH conjugates
are the two predominant pathways and only small amounts of the chloro
residues were found in forage and stover. No chloro residues were
detected in sorghum grain in two propazine metabolism studies that were
conducted. Griffin believes the metabolism is well characterized in
plants and animals and the pathways of metabolism are very similar to
those defined for other triazines. The metabolism profile supports the
use of an analytical enforcement method that accounts for parent
propazine and its two chloro metabolites, 2-amino-chloro- 6-isopropyl-
amino-s-triazine (G-30033) and 2-chloro-4,6-di-amino-s-triazine (G-
28273) in the raw agricultural commodity (RAC's) of grain sorghum and
further supports the current tolerance of 0.25 ppm to include the two
chloro metabolites.
2. Analytical method. A practical analytical method has been
submitted, as a part of the sorghum residue study. The method involves
extraction, evaporation solid phase clean-up
[[Page 36162]]
column and quantitation by high performance liquid chromotography
(HPLC) equipped with a ultraviolet ray (UV) detector. One aliquot is
used for assaying for propazine and G-30033 and another aliquot is used
for quantitating G-27283. The limit of quanitation (LOQ) for propazine
and each of its chloro metabolites in each raw agricultural commodities
(RAC) and each chloro residue is 0.05 ppm.
3. Magnitude of residues. A total of 13 sorghum field residue
trails were conducted in the major sorghum growing areas of the United
States. No quantifiable residues of parent or the two chloro
metabolites were detected in the RAC's of the 13 field residue studies
when treated at the 1x rate. Only four samples for sorghum forage
contained residues of G-28273 which were quantifiable and residues
ranged from 0.05 ppm to 0.087 ppm. The treatment rate for these studies
exceeded the maximum proposed use rate and the extrapolated range of
residues for the four samples was 0.024 to 0.069 ppm.
The RAC's of sorghum are only used as feed for cattle and poultry.
Only the grain is fed to chickens and there were no chloro residues
present in grain; therefore, no chloro residues would be expected in
eggs and poultry products. The level of chloro residues in forage and
fodder are sufficiently low in the metabolism and residue studies to
demonstrate that any potential transfer of propazine and its chloro
metabolites to milk and meat is not expected. For rotational crops, no
chloro residues were present in root and grain crops when planted more
than 129 days after treatment. Chloro residues were present in leafy
vegetables grown in soils with pH values above 7 and under inclimate
growing conditions. One field sample of wheat forage contained low
levels of parent propazine but this sample was taken at an interval
shorter than will be proposed on the label for plant back and, in
addition, the pH of the soil was above 7.
An amendment of the current tolerance of 0.25 ppm to include parent
propazine and its two chloro metabolites, G-30033 and G-28273, is
proposed for each of the RAC's of grain sorghum. The metabolism and
field residue results show that chloro residues of propazine should not
exceed 0.25 ppm in any of the RAC's. Potential transfer of propazine
and its two chloro metabolites to milk and meat is not expected.
Therefore, tolerances in milk, meat, poultry and eggs are not required.
The data show that root and grain crops can be rotated with sorghum
treated with propazine, but leafy vegetable crops should not be rotated
with sorghum in soils with pH values above 7.
B. Toxicological Profile
1. Acute toxicity. A complete battery of acute toxicity studies for
propazine technical was completed. The acute oral toxicity study
resulted in a LD50 of greater than 5,050 milligram kilogram
(mg/kg) for both sexes. The acute dermal toxicity in rabbits resulted
in an LD50 in either sex of greater than 5,050 mg/kg. The
acute inhalation study in rats resulted in an LC50 of
greater than 1.22 mg/l. Propazine was non-irritating to the skin of
rabbits in the primary dermal irritation study. In the primary eye
irritation study in rabbits, no irritation was noted. The dermal
sensitization study in guinea pigs indicated that propazine is not a
sensitizer. Based on these results, propazine technical is placed in
toxicity Category III.
2. Genotoxicity Propazine was positive without activation and
weakly positive with activation in an in vitro Chinese hamster cell
point mutation assay. It did not affect DNA repair in rat hepatocytes.
In in vivo assays, propazine was negative for both production anomalies
in Chinese hamster somatic cell nuclei in interphase and induction
structural damage (chromosome aberrations) in mouse spermatogonial
cells.
3. Reproductive and developmental toxicity. The potential maternal
and developmental toxicity of propazine were evaluated in rabbits.
Propazine technical was suspended in corn oil and administered orally
by gavage to three groups of 20 artificially inseminated New Zealand
White rabbits as a single daily dose from gestation days 6-18. In the
range-finding study, rabbits were dosed at levels of 0, 10, 50, 100,
200, and 400 milligram kilogram/day (mg/kg/day). Maternal toxicity was
exhibited by decreased defecation, body weight losses and decreased
food consumption during the treatment period at 50, 100, 200 and 400
mg/kg/day. Abortions also occurred at levels of 200 and 400 mg/kg/day.
Dose levels of 0, 2, 10, and 50 mg/kg/day were selected based on the
results of this study. In the definitive study, no test article related
deaths occurred at any dose level tested. The only clinical sign
observed was decreased defecation in the 50 mg/kg/ day group.
Inhibition of body weight gain occurred during the first 6 days of
dosing and inhibition of food consumption occurred throughout the
treatment period in the 50 mg/kg/day group. No other treatment related
findings were noted in the dams at any dose level. Intrauterine
parameters were unaffected by treatment. There were no treatment
related effects on fetal malformations or developmental variations.
The data from the developmental toxicity studies on propazine show
no evidence of a potential for developmental effects (malformations or
variations) at doses that are not maternally toxic. The no observed
adverse effect level (NOAEL) for maternal toxicity in rabbits was 10
mg/kg/day and the NOAEL for developmental toxicity was 50 mg/kg/day.
4. Subchronic toxicity. No test article related deaths occurred at
any dose level. Very minimal dermal irritation was noted in the 100 and
1,000 mg/kg/day females. Body weight gain was slightly inhibited in the
high dose group during weeks 0-1 (both sexes) and 2-3 (males only).
There were no treatment related effects on the clinical observations,
food consumption, hematology and serum chemistry parameters or organ
weights were observed at any dose level. Macroscopic and microscopic
examinations revealed no treatment related lesions at any dose level.
Based on the 21 day dermal study in rats, the NOAEL for systemic
toxicity was 100 mg/kg/day due to reduced body weight gain at 1,000 mg/
kg/day.
5. Chronic toxicity. Griffin conclude that the body weight gain and
survival data clearly indicate that the high dietary concentration of
1,000 ppm (68 mg/kg/day) for female rats exceeded the maximum tolerance
dose (MTD), and therefore, the high dose female group should be
excluded from any risk assessment or weight-of-evidence arguments
concerning this study. Additionally, the incidence of mammary gland
tumors in all doses in this study were within the range of current
laboratory historical control incidences and those reported by the
breeder, Charles River. No adverse treatment related effects were
observed at levels below the MTD (100 ppm or lower for females).
6. Animal metabolism. The absorption, distribution, excretion, and
metabolism of propazine (ring-UL-14C propazine) was investigated in
Sprague-Dawley CD rats. One group of rats was administered a single
oral dose at 1.0 mg/kg (low dose), one group was administered a single
oral dose at 100 mg/kg (high dose), and a third group was administered
fourteen consecutive oral daily doses of non-radioactive propazine at
1.0 mg/kg, followed by a single oral dose of 14C-propazine at 1.0 mg/kg
(consecutive dose group). A fourth group of animals (3 rats/sex) was
administered a single oral dose of the vehicle only (corn oil), and
served as
[[Page 36163]]
controls. Since propazine is not soluble in water, it was not possible
to include an intravenous dose group. Excretion patterns were very
similar in all dose groups. Nearly all of the radioactivity
administered was recovered in the excreta within 24 to 48 hours after
dosing. The majority of the administered radioactivity was excreted in
the urine (66.2-70.5%), and this finding shows that the majority of the
administered dose was bioavailable and rapidly absorbed from the
gastrointestinal tract. High performance liquid chromotography (HPLC)
analysis of the urine indicated a similar profile among all dose groups
and both sexes. The excretion of radioactivity in the feces was
significantly lower than in the urine (range: 19.9-28.6%) in all dose
groups and both sexes. Analysis of this radioactivity demonstrated a
relatively consistent pattern among the various dose groups with
females containing a quantitatively higher level of the parent
compound. The recovery of expired radioactivity was shown in a pilot
study to be negligible (< 0.1%), indicating little or no 14CO2
production during the metabolism of propazine.
Seven days post-treatment all animals were sacrificed and the total
radioactive residue was quantified in bone, brain, fat (visceral),
gastrointestinal tract (including contents), heart, kidney, liver,
lung, muscle (thigh), ovary, plasma, red blood cells (RBC), skin,
spleen, testis, thyroid, uterus, and residual carcass. Highest
concentrations were found in the RBCs of all dose groups (0.472-0.577
ppm parent equivalents at 1.0 mg/kg and 44.649-55.287 ppm at 100 mg/
kg). Residue concentration in the remaining tissues ranged from 0.007
to 0.468 ppm at the low and consecutive dose groups, and from 0.859 to
13.246 ppm at the high dose. Mean body burdens for the low, high, and
consecutive dose groups accounted for 10.3, 5.9 and 7.1% of the dose,
respectively. Material balances were quantitative and accounted for
102.5, 101.1 and 96.3% of the dose, respectively. Metabolite
characterization of excreta indicated a biotransformation pathway
consistent with historical metabolism of alkylated s-triazines.
Confirmed metabolite identification showed that propazine was
metabolized via Ndealkylation mechanisms and excreted in urine
primarily as the G-27283 metabolite (approximately 27% of the total
dose). Unmetabolized parent propazine was the predominant identified
compound in the feces (13.8% in the high dose male group). The fact
that a greater percentage of administered 14C-propazine was found in
the feces of the high dose group probably indicated some degree of
saturation of the absorption mechanism. Propazine technical is not
metabolized to breakdown products which accumulate in sufficient
quantities that can be reasonably expected to present any chronic
dietary risk.
7. Metabolite toxicology. The hydroxy metabolite of atrazine, an
analog of propazine has been shown not to exhibit carcinogenic effects.
8. Endocrine disruption. There is no evidence that propazine has
endocrinemodulation characteristics as demonstrated by the lack of
endocrine effects in developmental, subchronic and chronic studies.
C. Aggregate Exposure
1. Dietary exposure--i. Food. A dietary risk exposure study dietary
risk evaluation system (DRES) for Griffin for the purpose of estimating
dietary exposure to propazine residues. Grain sorghum is the only
proposed food or food use of propazine. Therefore, there exists no
potential for human consumption of crops treated with propazine.
Sorghum (grain, forage and stover) is, however, fed to livestock. Grain
is the only sorghum commodity fed to poultry. There are no chloro
residues, the residues of toxicological concern, in the grain. In turn,
there is no potential for poultry to be exposed to propazine or related
residues. Beef and dairy cattle are fed all sorghum commodities: grain,
forage, stover, and aspirated grain fractions. Therefore, in evaluating
potential human dietary exposure to propazine, the potential exposure
via secondary residues in meat and milk must be considered. The total
chloro residues for a goat dosed at 9.9 ppm in a metabolism study were
low. Specifically, the highest total residue while the lowest residue
of < 0.002 ppm was observed in kidney.
These tissues to feed ratios can then be combined with the worst-
case diets derived from a sorghum only ration which includes propazine
residues at the tolerance level of 0.25 ppm. (It should be noted that
this worst-case diet is not a ration that would be fed to cattle). The
results of this indicate that even under theoretically worst-case
conditions all meat and milk residues are extremely low (all less than
0.01 ppm; the LOQ in plant matrices is 0.05 ppm). In turn, there is no
potential for dietary exposure to propazine via secondary residues in
meat and milk. Therefore, tolerances for meat and milk are not required
for propazine.
ii. Drinking water. Griffin conclude that environmental fate and
behavior studies, including aerobic soil metabolism, field lysimeter,
and long term soil dissipation, indicate little potential for propazine
to reach surface or ground water from its proposed use on grain
sorghum. Griffin concludes that, there is little potential for dietary
exposure to propazine residues in water exists.
2. Non-dietary exposure. There are no residential uses for
propazine in the United States, therefore, there is no potential for
residential exposure.
D. Cumulative Effects
Because of the benefits of propazine, most of the propazine use on
sorghum will be substituted for other triazines and since the proposed
use rate is lower than the other triazines the cumulative will not
increase and could possibly be reduced as a result of registering
propazine for use on grain sorghum.
E. Safety Determination
The reference dose (RfD) is based on the rat chronic study. Using
the (no adverse effect level (NOAEL) of 5 mg/kg/day in this study and
an additional uncertainty factor (UF) of 300 (100 intraspecies and
interspecies uncertainty factor plus an additional uncertainty factor
of 3X for lack of a chronic study in dogs) an RfD of 0.02 mg/kg/day was
established as the chronic dietary endpoint.
1. U.S. population. In the DRES analysis referenced above, it was
determined that there is no potential exposure to propazine via
dietary, water, or nonoccupational routes.
2. Infants and children. In assessing the potential for additional
sensitivity of infants and children to residues of propazine, the
available developmental toxicity study and the potential for endocrine
modulation by propazine were considered. The data from the
developmental toxicity studies on propazine show no evidence of a
potential for developmental effects (malformations or variations) at
doses that are not maternally toxic. The developmental NOAELs and
lowest observed effect levels (LOAELs) were at higher dose levels (less
toxic), indicating no increase in susceptibility of developing
organisms. No evidence of endocrine effects were noted in any study. It
is therefore concluded that propazine poses no additional risk for
infants and children and no additional uncertainty factor is warranted.
Federal food, drug and cosmetic act (FFDCA) section 408 provides that
an additional safety factor for infants and children may be applied in
the case of threshold effects. Since, as discussed in the previous
section, the toxicology studies do not indicate that young animals are
[[Page 36164]]
any more susceptible than adult animals and the fact that the current
RfD calculated from the NOAEL from the rat chronic study already
incorporates a 300x uncertainty factor, Griffin believes that an
adequate margin of safety is, therefore, provided by the RfD
established by EPA. There is no evidence that propazine has endocrine-
modulation characteristics as demonstrated by the lack of endocrine
effects in developmental, subchronic, and chronic studies. There is no
potential exposure to propazine via dietary, water, or non-occupational
routes based on the proposed use on grain sorghum. No additional
uncertainty factor for infants and children is warranted based on the
completeness and reliability of the data base, the demonstrated lack of
increased risk to developing organisms, and the lack of endocrine-
modulating effects.
F. International Tolerances
There are no Codex Alimentarius Commission (CODEX) maximum residue
levels (MRLs) established for residues of propazine and its chloro
metabolites in or on raw agricultural commodities.
[FR Doc. 05-12015 Filed 6-21-05; 8:45 am]
BILLING CODE 6560-50-S